GlassScriptPhysician profile
Zain Husain
NPI 1225325848
$12,958.55
in general payments reported to CMS, 2019-2025
35 companies · $9,141 in 2025
The $9,141 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $623 · 2021: $369 · 2022: $560 · 2023: $723 · 2024: $883 · 2025: $9,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,050 · Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,050.00 |
| Food and Beverage | $2,697.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,507.64 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $444.83 | 2019-2024 | |
| Lilly USA, LLC | $440.87 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $395.76 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $295.28 | 2019-2025 | Dysport, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $258.17 | 2019-2025 | Cabtreo, Arazlo, Jublia |
| Arcutis Biotherapeutics, INC. | $245.27 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $228.31 | 2019-2023 | |
| Amgen INC. | $208.75 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $205.99 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $170.21 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $141.94 | 2019-2025 | Winlevi |
| Ucb, INC. | $137.55 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $135.10 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Allergan, INC. | $125.67 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $109.26 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $108.31 | 2019-2021 | |
| Organogenesis INC. | $97.71 | 2023-2025 | Puraply Am, Apligraf, Puraply |
| Merz North America, INC. | $85.52 | 2024-2025 | |
| Vyne Pharmaceuticals INC. | $80.38 | 2020-2021 | |
| Encore Dermatology INC. | $60.87 | 2019 | |
| Kyowa Kirin, INC. | $59.44 | 2022-2023 | Poteligeo |
| Epi Health, LLC | $56.72 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.40 | 2024 | Sotyktu |
| Pfizer INC. | $50.00 | 2025 | |
| Dermavant Sciences, INC. | $48.37 | 2023-2024 | Vtama |
| Almirall LLC | $44.18 | 2021 | |
| Botanix Sb INC | $41.23 | 2025 | Sofdra |
| Journey Medical Corporation | $23.22 | 2022 | |
| Revance Therapeutics, INC. | $20.99 | 2024 | Daxxify |
| Bioventus LLC | $17.49 | 2022 | |
| Sandoz INC. | $16.47 | 2023 | |
| Prugen, INC. Pharmaceuticals | $14.49 | 2019 | |
| Genentech USA, INC. | $13.88 | 2021 | |
| Celgene Corporation | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zain Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.